news
Pluristem’s post nuclear exposure study in primates a success
Pluristem Therapeutics announced the promising results of its non-human primates (NHP) pilot study for PLX-R18 as a treatment for Acute Radiation Syndrome (ARS).
List view / Grid view
U.S. Food and Drug Administration (FDA)
article
A new approach to Organ-on-a-Chip
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
article
Turning rare diseases into efficient targets with AI
BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution...
news
Wellcome Trust gives Polyphor CHF 2.3 million for antibiotic development
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
news
Latest revision on FDA combination product guidance presented at Pre-Filled Syringes Boston Summit
FDA Present on Regulatory Considerations for Combination Products at Pre-Filled Syringes East Coast this Spring...
news
Immunotherapy and gene therapy combination shows promise against brain tumours
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
news
New drug could prevent graft loss in pancreatic islet transplantation
5 December 2016 | By Niamh Louise Marriott, Digital Editor
In a rodent model of islet transplantation, ARA 290 markedly reduced transplantation-induced inflammation, resulting in a marked increase in islet survival...
news
ESCMID and ASM’s review need for new strategies and tactics to fight antimicrobial resistance
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the American Society for Microbiology (ASM) have just closed a joint conference in Vienna, which aimed to help researchers accelerate the development of new antimicrobials and to shed light on the challenges associated with antimicrobial resistance.
news
Myths that must be overcome to ensure successful commercialisation of biosimilars
10 October 2016 | By SMi Group
SMi's 3rd annual Biosimilars North America conference will be returning to Iselin, New Jersey, USA in November 2016...
news
FDA gives Roche 510k clearance for Treponema pallidum assay to aid syphilis diagnosis
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The Treponema pallidum assay is intended as an aid in the diagnosis of syphilis infection. The Roche Syphilis treponemal antibody test offers several...
news
HSRx antiviral drug tests effective against Zika virus
7 September 2016 | By Niamh Louise Marriott, Digital Content Producer
HSRx expects to begin human trials early in 2017 and will seek accelerated drug approval from the U.S. Food & Drug Administration...
news
Relmada’s d-Methadone receives Orphan Drug Designation
8 June 2016 | By Victoria White, Digital Content Producer
Relmada’s d-Methadone has received Orphan Drug designation from the US Food and Drug Administration for the management of postherpetic neuralgia...
news
Selvita files IND for dual PIM/FLT3 inhibitor, SEL24
18 April 2016 | By Victoria White, Digital Content Producer
SEL24 is a dual inhibitor of PIM and FLT3 kinases. It is the first molecule with this mechanism of action to progress to such stage of development...
news
FDA makes $2 million available to fund natural history studies in rare diseases
1 March 2016 | By Victoria White
The aim is to collect data on how specific rare diseases progress in individuals over time so that knowledge can inform and support product development and approval...
news
FDA clears first-in-human clinical study for MERS vaccine
19 November 2015 | By Victoria White
GeneOne Life Science and Inovio are co-developing the vaccine and plan to initiate the first human trial of a MERS vaccine before the end of the year...